Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1445-1454

  Ernsting, Mark J ^a   Tang, Wei Lun ^a   MacCallum, Noah W ^a   Li, Shyh Dar ^a  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

Biodistribution; Carboxymethylcellulose; Conjugated polymers; Docetaxel; Pharmacokinetics

Indexed keywords

ANTI-TUMOR EFFICACY; AREA UNDER THE CURVES; BIODISTRIBUTIONS; BLOOD CIRCULATION; CARBOXY METHYLCELLULOSE; DOCETAXEL; MOUSE MODELS; MOUSE TUMORS; NANOPARTICLE SELF-ASSEMBLY; NORMAL TISSUE; PEGYLATION; POLYMER CONJUGATE; REDUCED TOXICITY; TAXOTERE; TUMOR UPTAKE;

BIOLOGICAL ORGANS; BLOOD; CELL DEATH; CONJUGATED POLYMERS; DRUG PRODUCTS; MAMMALS; NANOPARTICLES; PHARMACOKINETICS; TOXICITY; TUMORS;

ENZYME INHIBITION;

CARBOXYLIC ACID; CARBOXYMETHYLCELLULOSE; DOCETAXEL; MACROGOL; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CHEMICAL STRUCTURE; CIRCULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RELEASE; DRUG UPTAKE; FOOD AND DRUG ADMINISTRATION; HEART; KIDNEY; LIVER; LUNG; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOXYMETHYLCELLULOSE SODIUM; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; INTRACELLULAR SPACE; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASM METASTASIS; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS; TAXOIDS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 83355169562     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.061     Document Type: Article

References (41)

1. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000, 44:235-249.
2. Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr Opin Drug Discov Devel 2005, 8:66-77.
3. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
4. Urien S., Barre J., Morin C., Paccaly A., Montay G., Tillement J.P. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 1996, 14:147-151.
5. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146.
6. Zhigaltsev I.V., Winters G., Srinivasulu M., Crawford J., Wong M., Amankwa L., et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010, 144:332-340.
7. Tagami T., Ernsting M.J., Li S.D. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J Control Release 2011, 152:303-309.
8. Tagami T., Foltz W.D., Ernsting M.J., Lee C.M., Tannock I.F., May J.P., et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials 2011, 32:6570-6578.
9. Tagami T., Ernsting M.J., Li S.D. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a brij surfactant using a robust in vitro system. J Control Release 2011, 154:290-297.
10. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
11. Jones S. Head-to-head: docetaxel challenges paclitaxel. EJC Supplements 2006, 4:4-8.
12. Shelley W.B., Talanin N., Shelley E.D. Polysorbate 80 hypersensitivity. Lancet 1995, 345:1312-1313.
13. Letchford K., Liggins R., Wasan K.M., Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 2009, 71:196-206.
14. Lim W.T., Tan E.H., Toh C.K., Hee S.W., Leong S.S., Ang P.C., et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 2010, 21:382-388.
15. Gaucher G., Marchessault R.H., Leroux J.C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release 2010, 143:2-12.
16. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
17. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
18. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
19. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002, 54:695-713.
20. O'Brien M.E., Socinski M.A., Popovich A.Y., Bondarenko I.N., Tomova A., Bilynsky B.T., et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:728-734.
21. Li C., Newman R.A., Wu Q.P., Ke S., Chen W., Hutto T., et al. Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 2000, 46:416-422.
22. Cera C., Palumbo M., Stefanelli S., Rassu M., Palu G. Water-soluble polysaccharide-anthracycline conjugates: biological activity. Anticancer Drug Des 1992, 7:143-151.
23. Inoue K., Kumazawa E., Kuga H., Susaki H., Masubuchi N., Kajimura T. CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv Exp Med Biol 2003, 519:145-153.
24. Soepenberg O., de Jonge M.J., Sparreboom A., de Bruin P., Eskens F.A., de Heus G., et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005, 11:703-711.
25. Uglea C.V., Parv A., Corjan M., Dumitriu A.D., Ottenbrite R.M. Biodistribution and antitumor activity induced by carboxymethylcellulose conjugates. J Bioactive Compatible Polym 2005, 20:571-583.
26. Namikoshi, H. US Patent: Carboxyalkyl acetyl celluloses, their salts and a process for the preparation of them. USPTO; 1985.
27. Wijsman J.H., Jonker R.R., Keijzer R., van de Velde C.J., Cornelisse C.J., van Dierendonck J.H. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem 1993, 41:7-12.
28. Ringsdorf H. Structure and properties of pharmacologically active polymers. Journal of Polymer Science: Polym Symposia 1975, 51:135-153.
29. Yang D., Yu L., Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers 2011, 3:17-42.
30. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003, 2:347-360.
31. Liu J., Zahedi P., Zeng F., Allen C. Nano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxel. J Pharm Sci 2008, 97:3274-3290.
32. Wang X., Li J., Wang Y., Cho K.J., Kim G., Gjyrezi A., et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
33. Li C., Yu D.F., Newman R.A., Cabral F., Stephens L.C., Hunter N., et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998, 58:2404-2409.
34. Sugahara S., Kajiki M., Kuriyama H., Kobayashi T.R. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release 2007, 117:40-50.
35. Bradshaw-Pierce E.L., Eckhardt S.G., Gustafson D.L. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 2007, 13:2768-2776.
36. Fernandez-Urrusuno R., Fattal E., Rodrigues J.M., Feger J., Bedossa P., Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 1996, 31:401-408.
37. Ernsting M.J., Tang W.L., MacCallum N.W., Li S.D. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. Bioconjug Chem 2011, Accepted Oct 2011.
38. Hilkens P.H., Verweij J., Vecht C.J., Stoter G., van den Bent M.J. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann Oncol 1997, 8:187-190.
39. Li C., Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008, 60:886-898.
40. Sparreboom A., Scripture C.D., Trieu V., Williams P.J., De T., Yang A., et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol). Clin Cancer Res 2005, 11:4136-4143.
41. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-1324.